慢性功能性便秘患者补充益生菌、益生元和合生元:随机、双盲、安慰剂对照试点临床试验。

IF 3.8 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Gastroenterology Report Pub Date : 2024-11-11 eCollection Date: 2024-01-01 DOI:10.1093/gastro/goae101
Ana Terrén Lora, Bruno F Penadés, Sara López Oliva, Sari Arponen, Gülşah Okutan, Guerthy Melissa Sánchez Niño, Ismael San Mauro Martín
{"title":"慢性功能性便秘患者补充益生菌、益生元和合生元:随机、双盲、安慰剂对照试点临床试验。","authors":"Ana Terrén Lora, Bruno F Penadés, Sara López Oliva, Sari Arponen, Gülşah Okutan, Guerthy Melissa Sánchez Niño, Ismael San Mauro Martín","doi":"10.1093/gastro/goae101","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Functional constipation includes a set of gastrointestinal symptoms unexplainable by an identifiable underlying physical cause or pathology. The prevalence of this condition is high and there is a need to develop strategies to reduce it. Probiotics, prebiotics, and synbiotics may be an alternative treatment for chronic functional constipation.</p><p><strong>Methods: </strong>To compare the efficacy of dietary supplementation on symptoms of patients who suffer from chronic functional constipation. An exploratory, randomized, double-blind, placebo-controlled pilot clinical trial was conducted with 74 patients diagnosed with chronic functional constipation who were divided into four treatment groups-Group A: probiotics; Group B: prebiotics; Group C: synbiotics; Group D: placebo. Each patient was treated for 8 weeks. At the beginning and end of treatment, data were collected by administering questionnaires and scales, including the Bristol stool scale, on gastrointestinal symptoms, bowel movements, and sociodemographic and anthropometric characteristics.</p><p><strong>Results: </strong>Stool frequency increased in all four study groups, and greatest difference was observed in the synbiotics group (2.8 ± 1.3 vs. 5.9 ± 2.6; <i>P</i> < 0.001). Stool consistency improved only in the active treatment groups. Based on the evaluation of gastrointestinal symptoms, participants treated with prebiotics, probiotics and synbiotics showed the greatest improvement in abdominal pain (8.28 ± 2.63 vs. 6.56 ± 2.62; <i>P</i> = 0.009), gastroesophageal reflux (4.60 ± 2.66 vs. 3.45 ± 2.42; <i>P</i> = 0.039) and constipation symptoms (13.00 ± 3.97 vs. 8.71 ± 3.35; <i>P</i> = 0.003), respectively. As for quality of life, the main changes were observed in physical health domains, with a placebo effect.</p><p><strong>Conclusions: </strong>The present study provides evidence supporting the efficacy of dietary supplementation with probiotics, prebiotics, and synbiotics in patients with chronic functional constipation after 8 weeks of treatment.</p>","PeriodicalId":54275,"journal":{"name":"Gastroenterology Report","volume":"12 ","pages":"goae101"},"PeriodicalIF":3.8000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552633/pdf/","citationCount":"0","resultStr":"{\"title\":\"Supplementation with probiotics, prebiotics, and synbiotics in patients with chronic functional constipation: a randomized, double-blind, placebo-controlled pilot clinical trial.\",\"authors\":\"Ana Terrén Lora, Bruno F Penadés, Sara López Oliva, Sari Arponen, Gülşah Okutan, Guerthy Melissa Sánchez Niño, Ismael San Mauro Martín\",\"doi\":\"10.1093/gastro/goae101\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Functional constipation includes a set of gastrointestinal symptoms unexplainable by an identifiable underlying physical cause or pathology. The prevalence of this condition is high and there is a need to develop strategies to reduce it. Probiotics, prebiotics, and synbiotics may be an alternative treatment for chronic functional constipation.</p><p><strong>Methods: </strong>To compare the efficacy of dietary supplementation on symptoms of patients who suffer from chronic functional constipation. An exploratory, randomized, double-blind, placebo-controlled pilot clinical trial was conducted with 74 patients diagnosed with chronic functional constipation who were divided into four treatment groups-Group A: probiotics; Group B: prebiotics; Group C: synbiotics; Group D: placebo. Each patient was treated for 8 weeks. At the beginning and end of treatment, data were collected by administering questionnaires and scales, including the Bristol stool scale, on gastrointestinal symptoms, bowel movements, and sociodemographic and anthropometric characteristics.</p><p><strong>Results: </strong>Stool frequency increased in all four study groups, and greatest difference was observed in the synbiotics group (2.8 ± 1.3 vs. 5.9 ± 2.6; <i>P</i> < 0.001). Stool consistency improved only in the active treatment groups. Based on the evaluation of gastrointestinal symptoms, participants treated with prebiotics, probiotics and synbiotics showed the greatest improvement in abdominal pain (8.28 ± 2.63 vs. 6.56 ± 2.62; <i>P</i> = 0.009), gastroesophageal reflux (4.60 ± 2.66 vs. 3.45 ± 2.42; <i>P</i> = 0.039) and constipation symptoms (13.00 ± 3.97 vs. 8.71 ± 3.35; <i>P</i> = 0.003), respectively. As for quality of life, the main changes were observed in physical health domains, with a placebo effect.</p><p><strong>Conclusions: </strong>The present study provides evidence supporting the efficacy of dietary supplementation with probiotics, prebiotics, and synbiotics in patients with chronic functional constipation after 8 weeks of treatment.</p>\",\"PeriodicalId\":54275,\"journal\":{\"name\":\"Gastroenterology Report\",\"volume\":\"12 \",\"pages\":\"goae101\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-11-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552633/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gastroenterology Report\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/gastro/goae101\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterology Report","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/gastro/goae101","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:功能性便秘包括一系列无法用可识别的潜在生理原因或病理原因解释的胃肠道症状。这种情况的发病率很高,因此有必要制定减少这种情况的策略。益生菌、益生元和合成益生菌可能是治疗慢性功能性便秘的替代疗法:方法:比较膳食补充剂对慢性功能性便秘患者症状的疗效。我们对 74 名被诊断为慢性功能性便秘的患者进行了一项探索性、随机、双盲、安慰剂对照试验性临床试验,这些患者被分为四个治疗组--A 组:益生菌;B 组:益生元;C 组:合成益生菌;D 组:安慰剂。每位患者接受为期 8 周的治疗。在治疗开始和结束时,通过问卷和量表(包括布里斯托尔粪便量表)收集有关胃肠道症状、排便情况、社会人口学和人体测量特征的数据:所有四个研究组的大便次数都有所增加,其中益生菌组(2.8 ± 1.3 vs. 5.9 ± 2.6; P P = 0.009)、胃食管反流组(4.60 ± 2.66 vs. 3.45 ± 2.42; P = 0.039)和便秘症状组(13.00 ± 3.97 vs. 8.71 ± 3.35; P = 0.003)的差异最大。至于生活质量,主要的变化出现在身体健康领域,并有安慰剂效应:本研究为慢性功能性便秘患者在接受 8 周治疗后补充益生菌、益生元和合成益生菌的疗效提供了证据支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Supplementation with probiotics, prebiotics, and synbiotics in patients with chronic functional constipation: a randomized, double-blind, placebo-controlled pilot clinical trial.

Background: Functional constipation includes a set of gastrointestinal symptoms unexplainable by an identifiable underlying physical cause or pathology. The prevalence of this condition is high and there is a need to develop strategies to reduce it. Probiotics, prebiotics, and synbiotics may be an alternative treatment for chronic functional constipation.

Methods: To compare the efficacy of dietary supplementation on symptoms of patients who suffer from chronic functional constipation. An exploratory, randomized, double-blind, placebo-controlled pilot clinical trial was conducted with 74 patients diagnosed with chronic functional constipation who were divided into four treatment groups-Group A: probiotics; Group B: prebiotics; Group C: synbiotics; Group D: placebo. Each patient was treated for 8 weeks. At the beginning and end of treatment, data were collected by administering questionnaires and scales, including the Bristol stool scale, on gastrointestinal symptoms, bowel movements, and sociodemographic and anthropometric characteristics.

Results: Stool frequency increased in all four study groups, and greatest difference was observed in the synbiotics group (2.8 ± 1.3 vs. 5.9 ± 2.6; P < 0.001). Stool consistency improved only in the active treatment groups. Based on the evaluation of gastrointestinal symptoms, participants treated with prebiotics, probiotics and synbiotics showed the greatest improvement in abdominal pain (8.28 ± 2.63 vs. 6.56 ± 2.62; P = 0.009), gastroesophageal reflux (4.60 ± 2.66 vs. 3.45 ± 2.42; P = 0.039) and constipation symptoms (13.00 ± 3.97 vs. 8.71 ± 3.35; P = 0.003), respectively. As for quality of life, the main changes were observed in physical health domains, with a placebo effect.

Conclusions: The present study provides evidence supporting the efficacy of dietary supplementation with probiotics, prebiotics, and synbiotics in patients with chronic functional constipation after 8 weeks of treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Gastroenterology Report
Gastroenterology Report Medicine-Gastroenterology
CiteScore
4.60
自引率
2.80%
发文量
63
审稿时长
8 weeks
期刊介绍: Gastroenterology Report is an international fully open access (OA) online only journal, covering all areas related to gastrointestinal sciences, including studies of the alimentary tract, liver, biliary, pancreas, enteral nutrition and related fields. The journal aims to publish high quality research articles on both basic and clinical gastroenterology, authoritative reviews that bring together new advances in the field, as well as commentaries and highlight pieces that provide expert analysis of topical issues.
期刊最新文献
TNFSF15 variant predicts disease progression in Chinese patients with Crohn's disease. Supplementation with probiotics, prebiotics, and synbiotics in patients with chronic functional constipation: a randomized, double-blind, placebo-controlled pilot clinical trial. New perspectives in liver diseases with challenges. A comprehensive review and update on acute severe lower gastrointestinal bleeding in Crohn's disease: a management algorithm. Gasdermin E mediates pyroptosis in the progression of hepatocellular carcinoma: a double-edged sword.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1